论文部分内容阅读
目的了解对溃疡性结肠炎患者用肠炎康、美沙拉嗪两者联合治疗的效果及该方案的安全性。方法纳入对象来自本院2015-2016年期间收治各种原因诱发溃疡性结肠炎患者230例,采取随机数字表法将患者以每组115例分为对照组与观察组,溃疡性结肠炎干预方式分别为单纯用美沙拉嗪与联合肠炎康。对比疗效及安全性。结果根据患者症状改善和电镜检查结果评估疗效,提示观察组判定无效患者例数明显低于对照组,总有效率经对比统计,提示有意义(P<0.05);治疗期间及疗程后随访均未发现2组患者出现严重不良反应,顺利完成治疗。结论对溃疡性结肠炎患者特别是因癌症引发该病的,在制定治疗方案时在常规干预基础上联合肠炎康不仅能够极大程度地提升改善效果,同时并不增加诱发不良反应的可能性,对患者生活质量不造成影响,高效安全,值得临床推广。
Objective To understand the effect of combined treatment of enteritis and mesalazine on patients with ulcerative colitis and the safety of the regimen. Methods A total of 230 patients with ulcerative colitis induced by various causes from 2015 to 2016 in our hospital were enrolled. The patients were divided into control group and observation group with 115 cases in each group according to random number table. The intervention of ulcerative colitis Respectively with simple mesalazine and enteric Kang. Comparison of efficacy and safety. Results According to the improvement of symptoms and the results of electron microscopic examination, the number of patients in the observation group was significantly lower than that of the control group. The total effective rate was statistically significant (P <0.05), and no significant difference was found between the two groups during the treatment and post-treatment follow-up Two groups of patients found serious adverse reactions, the successful completion of treatment. Conclusions In patients with ulcerative colitis, especially caused by cancer, the combination of conventional treatment with enteritis may not only greatly improve the effectiveness of the treatment plan, but also not increase the possibility of adverse reactions, Does not affect the quality of life of patients, efficient and safe, it is worth clinical promotion.